Active, Not Recruiting
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
NCT06187506
- Conditions
- Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, China